Microbot Medical Data Backs Liberty Endovascular Surgical Robot

Microbot Medical presented data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting.

The data concluded that robotic endovascular procedures using the company’s Liberty endovascular robotic system are feasible and significantly minimize radiation exposure.

Successful robotic navigation was achieved in every case with a 100% success rate. There were no adverse device events reported through the duration of follow-up.

The average difference in radiation exposure between operator and control was (-)29.8 µS, which translates to a mean 92% relative reduction in radiation exposure. Median robotic navigation time to target was also three minutes.

Physicians participating in the trial reported that Liberty performed as planned with a 100% satisfaction rate.

“We are very satisfied with the clinical data, as well as with the investigators’ feedback in terms of the short learning curve and intuitive operation of the device,” commented Dr. Juan Diaz-Cartelle, Microbot Medical’s chief medical officer. “We are looking forward to working with interventional physicians and staff upon FDA’s clearance.”

“The ACCESS-PVI data and the performance of the system throughout the study reflect the hard work that the team has put into LIBERTY over the past few years,” said Harel Gadot, Microbot’s chairman, CEO, and president. “We are extremely pleased with the results in all aspects. As we shift focus to building our commercial capabilities and preparing for launch, we are confident that LIBERTY will be well received in the market.”

The company submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the Liberty endovascular robotic system in December 2024.